Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4421 Head-to-head comparison of 18F-AlF-NOTA-JR11 PET/MR and 68Ga-DOTATATE PET/CT in patients with neuroendocrine tumours: A prospective study

Introduction: PET/MR combines the molecular advantages of PET with excellent morphologic and anatomic delineation of MRI.18F-AlF-NOTA-JR11, a novel SSTR antagonist with a high affinity for SSTR2, has the potential to perform better than SSTR agonists in neuroendocrine tumour imaging.

Conference:

Presenting Author: Yu J

Authors: Jin X, Xie Q, Lu M, Li J, Yang Z,

Keywords: neuroendocrine tumour, PET/MR, SSTR antagonist, 18F-AlF-NOTA-JR11,

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#4309 Head-to-head comparison of 18F-AIF-NOTA-octreotide and 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine neoplasms

Introduction: 18F-AIF-NOTA-octreotide (F-Oc) is a radiolabelled SSA emerging as a potential alternative to 68Ga-DOTATATE (Ga-DT) due to logistical advantages. Recent studies indicate that F-Oc has comparable diagnostic accuracy to Ga-DT in neuroendocrine neoplasm (NEN) and, in some cases, can identify a greater number of lesions.

Conference:

Presenting Author: Bel-Ange A

Authors: Ben-Haim S, Bel-Ange A, Chicheportichee A, Maimon O, Aburbeh G,

Keywords: 68Ga-DOTATATE, NEN, 18F-AIF-NOTA-octreotide,

#4290 TB-161-Dotatate and Lu-177-Dotatate as a tandem therapy

Introduction: Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express cell-membrane specific peptide receptors, such as somatostatin receptors.

Conference:

Presenting Author:

Authors: Hambapersad T, Maharaj M,

Keywords: TB-161-Dotatate, Lu-177-Dotatate, Tandem,

#3722 A novel and potent Pb-212 alpha-particle therapy for NETs – Complete responses in mouse models to global clinical translation for NET patients

Introduction: A novel SSTR2 targeted peptide (VMT-alpha-NET) has been developed. Promising preclinical data have led to the initiation of multiple Phase 1 clinical trials in the United States for Pb-203 image-guided Pb-212 based alpha-particle therapy for NETs.

Conference:

Presenting Author: Schultz M

Authors: Schultz M, Johnson F, Li M, Liu D, McDonald M,

Keywords: NET, neuroendocrine tumor, alpha therapy, Pb-212, Pb-203, SPECT,